Nelfinavir plasma concentrations are low during pregnancy

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
Jeannine F J B NellenJan M Prins

Abstract

Plasma nelfinavir concentration ratios (CRs) were calculated for all pregnant (n=27) and nonpregnant (n=48) human immunodeficiency virus type 1-infected women receiving the drug who visited our outpatient clinic. In pregnant women, mean and median nelfinavir CRs were significantly lower (P=.02 and P=.04, respectively), and 51% of the CRs were below the clinically relevant threshold of 0.90, compared with 35% of the CRs in nonpregnant women. After we adjusted for confounders, we found that the mean nelfinavir CR was 34% lower in pregnant women (P=.02). With targeted interventions, subsequent CRs in pregnant women showed a significant increase (median increase, 0.31; P=.01).

References

Jul 1, 1982·Clinical Pharmacokinetics·E Perucca, A Crema
Dec 10, 1997·Clinical Pharmacokinetics·R LoebsteinG Koren
Jan 1, 1997·AIDS·A ReggyM Rogers
Jul 27, 2000·Obstetrics and Gynecology·B B Little
Dec 14, 2001·HIV Clinical Trials·E P AcostaUNKNOWN Pediatric AIDS Clinical Trials Group 386 Protocol Team
Jan 24, 2002·Therapeutic Drug Monitoring·Ronen Loebstein, Gideon Koren
Jun 22, 2002·Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences·C MarzoliniL A Decosterd
Jan 28, 2003·Therapeutic Drug Monitoring·David M BurgerUNKNOWN ATHENA Study Group
Jun 24, 2003·AIDS·Bradley W KoselFrancesca T Aweeka

❮ Previous
Next ❯

Citations

Feb 14, 2013·Drugs·Nisha Andany, Mona R Loutfy
May 23, 2007·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Deven PatelMarie-Louise Newell
May 4, 2005·AIDS·Sarah TimmermansUNKNOWN Dutch HMF Study Group
Nov 17, 2009·AIDS·Roger ParedesUNKNOWN Women and Infants Transmission Study (WITS) Group
Mar 11, 2010·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Risa M HoffmanMatthew Chersich
Jul 19, 2011·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Giovanina M EllisUNKNOWN P1022 Study Team
Mar 28, 2008·HIV Medicine·J F J B NellenJ M Prins
Mar 19, 2009·The Journal of Pharmacology and Experimental Therapeutics·Huixia ZhangJashvant D Unadkat
May 30, 2009·The Journal of Pharmacology and Experimental Therapeutics·Huixia ZhangJashvant D Unadkat
May 26, 2006·Antimicrobial Agents and Chemotherapy·Déborah HirtSaïk Urien
Jan 15, 2013·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Michelle S CespedesJudith A Aberg
May 28, 2005·Expert Review of Anti-infective Therapy·Rebecca A Clark, Kathleen E Squires
Jul 27, 2006·Expert Opinion on Drug Metabolism & Toxicology·Montserrat Olmo, Daniel Podzamczer
Mar 31, 2010·Expert Opinion on Drug Safety·Xia LiuFujie Zhang
Feb 5, 2010·Infectious Diseases in Obstetrics and Gynecology·Adriana WeinbergMyron J Levin
Mar 31, 2009·Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology·Adriana WeinbergMyron J Levin
Jan 26, 2006·Basic & Clinical Pharmacology & Toxicology·Ulrik Stenz Justesen
Jun 10, 2008·British Journal of Clinical Pharmacology·Matthieu RoustitFrançoise Stanke-Labesque
Nov 2, 2016·PLoS Medicine·Gali ParienteGideon Koren
Mar 25, 2009·Infection·G CarosiUNKNOWN Italian Working Group for the Women with HIV Management Guidelines
Dec 7, 2005·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Rebecca Clark
Dec 31, 2010·Therapeutic Drug Monitoring·Matthijs van LuinDavid M Burger
Oct 18, 2005·Drugs·Caroline M PerryRisto S Cvetković

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.